Its peer group, by the way, is small medical technology companies, mainly ones making products for laser and cosmetic therapies.
Tomorrow Syneron will be publishing its fourth-quarter and 2005 financial statements.
Unterberg predicts 38% quarterly revenue growth against the parallel quarter to $24.2 million, and a 51% leap in profit to 45 cents per share.
The company guided investors to expect $24 million sales. In January 2006, it lowered its guidance downward from $27.3 million - $28.3 million, which helped it lose 40% of its market cap since mid-December.
The company's market cap had been more than a billion dollars but has sunk to $685 million.
At the time Syneron tried to soften the blow, reporting that its fourth-quarter results will not be including transactions worth between $3 million to $4 million. The devices had been shipped and if these transactions were included, its sales would have been $27 million, as expected.
The company has not yet provided guidance for 2006. Wall Street expects earnings in the range of $1.85 to $2.42 per share on revenues of $106.8 million to $127 million.
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe todaySubscribe now